- Zacks•3 days ago
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
- Business Wire•4 days ago
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation status to Rituxan® for pemphigus vulgaris, a rare, serious and life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.2 FDA Breakthrough Therapy Designation is intended to expedite the development and review ...
- Investor's Business Daily•5 days ago
Dow leader Merck swiped share from rival Bristol-Myers as Roche remained flat, according to a health tracker.
RO.SW : Summary for ROCHE I - Yahoo Finance
Roche Holding AG (RO.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
|Day's Range||251.25 - 253.25|
|52 Week Range||221.80 - 265.50|
|PE Ratio (TTM)||22.70|
|Dividend & Yield||8.22 (3.24%)|
|1y Target Est||N/A|